Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altamira Therapeutics Ltd
(NQ:
CYTO
)
1.560
UNCHANGED
Streaming Delayed Price
Updated: 3:51 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Altamira Therapeutics Ltd
< Previous
1
2
3
4
Next >
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo
April 10, 2023
Via
ACCESSWIRE
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
March 22, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics’ SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model
March 15, 2023
Via
ACCESSWIRE
Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties
March 03, 2023
Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet
Via
Spotlight Growth
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
March 03, 2023
Via
ACCESSWIRE
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
February 27, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing
February 14, 2023
Via
ACCESSWIRE
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
February 07, 2023
Via
ACCESSWIRE
Altamira Therapeutics Provides Business Update
January 27, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
January 24, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
January 10, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Year-End 2022 Business Update
December 19, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia
December 02, 2022
Via
ACCESSWIRE
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
November 30, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
November 30, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability
November 22, 2022
Via
ACCESSWIRE
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
November 10, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
November 09, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
November 08, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Reverse Stock Split
October 24, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
October 21, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Participate at RNA Leaders USA Congress
October 13, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia
October 03, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
July 28, 2022
•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint...
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal
July 12, 2022
HAMILTON, BERMUDA / ACCESSWIRE / July 12, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical...
From
Altamira Therapeutics Ltd.
Via
AccessWire
Topics
Death
Exposures
Death
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan
June 29, 2022
Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
June 27, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
Product Safety
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19
June 23, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo
June 13, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics Ltd.
Via
AccessWire
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements
June 09, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.